RecruitingPhase 2NCT05754684

Quadruple Immunotherapy for Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hong Kong Children's Hospital
Principal Investigator: Daniel Cheuk
Hong Kong Children's Hospital
Intervention: Natural killer cell(biological)
Enrollment: 29 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2025

Study locations (1)

Hong Kong Children's Hospital, Hong Kong, Hong Kong

Collaborators

The University of Hong Kong

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05754684 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2, PHASE3NCT07549321
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Renaissance Pharma Ltd.
RECRUITINGPHASE1, PHASE2NCT06625190
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
RECRUITINGPHASE1NCT07172958
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Children's National Research Institute
RECRUITINGPHASE2NCT07085338
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
St. Jude Children's Research Hospital
RECRUITINGPHASE1, PHASE2NCT07399821
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Princess Maxima Center for Pediatric Oncology
RECRUITINGPHASE1NCT06995872
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Cancer Institute (NCI)
RECRUITINGPHASE1, PHASE2NCT06814496
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
RECRUITINGPHASE1NCT07087002
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Stanford University

See all trials for Neuroblastoma →

← Back to all trials